Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus (Articolo in rivista) (literal)

Anno

• 2007-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.1038/sj.clpt.6100146 (literal)

Alternative label

• Berria R.; Glass L.; Mahankali A.; Miyazaki Y.; Monroy A.; De Filippis D.; Cusi K.; Cersosimo E.; Defronzo R. A.; Gastaldelli A. (2007)
  Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus
  in Clinical pharmacology and therapeutics
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Berria R.; Glass L.; Mahankali A.; Miyazaki Y.; Monroy A.; De Filippis D.; Cusi K.; Cersosimo E.; Defronzo R. A.; Gastaldelli A. (literal)

Pagina inizio

• 275 (literal)

Pagina fine

• 281 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

• http://www.ncbi.nlm.nih.gov/pubmed/17361126 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 82 (literal)

Rivista

• Clinical pharmacology and therapeutics (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

• In: Clinical Pharmacology & Therapeutics, vol. 82 pp. 275 - 281. Clin Pharmacol Ther, 2007. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

• 3 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Univ Texas, Hlth Sci Ctr, Dept Med, Div Diabet, San Antonio, TX 78285 USA Case Western Reserve Univ, Metrohlth Med Ctr, Ob Gyn Dept, Cleveland, OH 44106 USA CNR, Inst Clin Physiol, I-56100 Pisa, Italy (literal)

Titolo

• Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus (literal)

Abstract

• Peripheral edema, mild weight gain, and anemia are often observed in type II diabetic patients treated with thiazolidinediones (TZDs). Small decreases in hemoglobin (Hb) and hematocrit (Hct) appear to be a class effect of TZDs and are generally attributed to fluid retention, although experimental data are lacking. We analyzed 50 patients with type II diabetes mellitus undergoing either placebo or pioglitazone (PIO, 45 mg/day) for 16 weeks. Before and after therapy, we measured Hb/Hct and used (3)H(2)O and bioimpedance to quantitate total body water (TBW), extracellular water, and fat-free mass. The majority (89%) of the increment in body weight was accounted for by increased body fat. Hb and Hct fell significantly in the PIO group (-0.9+/-0.2 g/dl, -2.4+/-0.5%, both P0.0001), without change in TBW. A decline in white blood cell (-0.8+/-0.1 x 10(3)/mm(3), P0.0001) and platelet (-15+/-6 x 10(3)/mm(3), P0.02) counts was seen after PIO. In conclusion, the small decreases in Hb/Hct observed after 16 weeks of PIO treatment cannot be explained by an increase in TBW. Other causes, such a mild marrow suppressive effect, should be explored. (literal)

Prodotto di

• Tassonomia clinica molecolare - Tassonomia clinica molecolare (ME.P05.003.001) (Modulo)
• Istituto di fisiologia clinica (IFC) (Istituto)

Autore CNR

• AMALIA GASTALDELLI (Persona)

Insieme di parole chiave

• Keywords of "Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus" (Insieme di parole chiave)

Incoming links:

Autore CNR di

• AMALIA GASTALDELLI (Persona)

Prodotto

• Istituto di fisiologia clinica (IFC) (Istituto)
• Tassonomia clinica molecolare - Tassonomia clinica molecolare (ME.P05.003.001) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Clinical pharmacology and therapeutics (Rivista)

Insieme di parole chiave di

• Keywords of "Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus" (Insieme di parole chiave)